Stock of the Day

October 13, 2020

CareDx (CDNA)

$39.73
-$0.61 (-1.5%)
Market Cap: $2.05B

About CareDx

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Today's Trend

CareDx, Inc. (CDNA) — shares are down today despite several positive developments after the company reported Q1 results and provided FY‑2026 revenue guidance. Below are the key items investors should know and how they may affect the stock.

  • Q1 results beat expectations: CareDx reported $0.34 EPS and $117.7M revenue, well above consensus and up ~39% year‑over‑year — evidence of accelerating top‑line growth. Zacks: CareDx Q1 Earnings
  • FY‑2026 revenue guidance raised: CareDx gave revenue guidance of $447.0M–$465.0M vs. street ~$439.9M, signaling stronger-than-expected growth for the year and supporting upside to estimates. Company FY‑2026 Guidance (slide deck)
  • Analyst price target upgrade: BTIG raised its price target to $28 and reinstated/maintained a Buy rating, implying meaningful upside vs. the current share level and potentially supporting buyer interest. Benzinga: BTIG PT Raise
  • Strategic M&A: CareDx agreed to acquire Naveris, adding a Medicare‑reimbursed, blood‑based MRD surveillance test in oncology — diversifies revenues and expands diagnostics addressable market beyond transplant. BusinessWire: Naveris Acquisition
  • Earnings call materials available: Management’s presentation and transcript provide detail on margin outlook, integration plans for Naveris, and drivers behind the revenue guide — useful for assessing execution risk. Seeking Alpha: Q1 Presentation
  • Profitability still negative: Despite the beat, CareDx remains unprofitable on net margin and ROE metrics, which leaves the stock sensitive to execution, margin pressure from M&A, and market sentiment. Company: Q1 Conference Call Slides

Bottom line for investors: the quarter and raised revenue guide are material positives and support upside, as reinforced by BTIG’s higher target. However, the company remains unprofitable and the Naveris acquisition introduces integration and execution risk — factors likely driving intraday volatility. Watch upcoming analyst revisions, integration details for Naveris, and next quarter’s margin trajectory for confirmation of the bullish case.

← Previous Stock of the DayNext Stock of the Day →

Recent News